In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor

Michiel S. Van Der Heijden, Jonathan R. Brody, David A. Dezentje, Eike Gallmeier, Steven C. Cunningham, Michael J. Swartz, Angelo Michael Demarzo, G. Johan A Offerhaus, William H. Isacoff, Ralph H Hruban, Scott E Kern

Research output: Contribution to journalArticle

Abstract

Purpose: BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based on the genetic profile of the tumor. Experimental Design: Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway, PL11 (FANCC-mutated) and Hs766T (FANCG-mutated), as Well as several parental pancreatic cancer cell lines with or without mutations in the Fanconi anemia/BRCA2 pathway, were assayed for in vitro and in vivo sensitivities to various chemotherapeutic agents. Results: A distinct dichotomy of drug responses was observed. Fanconi anemia-defective cancer cells were hypersensitive to the cross-linking agents mitomycin C (MMC), cisplatin, chlorambucil, and melphalan but not to 5-fluorouracil, gemcitabine, doxorubicin, etoposide, vinblastine, or paclitaxel. Hypersensitivity to cross-linking agents was confirmed in vivo; FANCC-deficient xenografts of PL11 and BRCA2-deficient xenografts of CAPAN1 regressed on treatment with two different regimens of MMC whereas Fanconi anemia-proficient xenografts did not. The MMC response comprised cell cycle arrest/apoptosis, and necrosis. Xenografts of PL11 also regressed after a single dose of cyclophosphamide whereas xenografts of genetically complemented PL11FANCC did not. Conclusios: MMC or other cross-linking agents as a clinical therapy for pancreatic cancer patients with tumors harboring defects in the Fanconi anemia/BRCA2, pathway should be specifically investigated.

Original languageEnglish (US)
Pages (from-to)7508-7515
Number of pages8
JournalClinical Cancer Research
Volume11
Issue number20
DOIs
StatePublished - Oct 15 2005

Fingerprint

Fanconi Anemia
Pancreatic Neoplasms
Heterografts
Mitomycin
Neoplasms
gemcitabine
Hypersensitivity
Chlorambucil
Therapeutics
Cell Line
Mutation
Melphalan
Vinblastine
Etoposide
Paclitaxel
Cell Cycle Checkpoints
Fluorouracil
Doxorubicin
Cyclophosphamide
Cisplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Der Heijden, M. S., Brody, J. R., Dezentje, D. A., Gallmeier, E., Cunningham, S. C., Swartz, M. J., ... Kern, S. E. (2005). In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor. Clinical Cancer Research, 11(20), 7508-7515. https://doi.org/10.1158/1078-0432.CCR-05-1048

In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor. / Van Der Heijden, Michiel S.; Brody, Jonathan R.; Dezentje, David A.; Gallmeier, Eike; Cunningham, Steven C.; Swartz, Michael J.; Demarzo, Angelo Michael; Offerhaus, G. Johan A; Isacoff, William H.; Hruban, Ralph H; Kern, Scott E.

In: Clinical Cancer Research, Vol. 11, No. 20, 15.10.2005, p. 7508-7515.

Research output: Contribution to journalArticle

Van Der Heijden, MS, Brody, JR, Dezentje, DA, Gallmeier, E, Cunningham, SC, Swartz, MJ, Demarzo, AM, Offerhaus, GJA, Isacoff, WH, Hruban, RH & Kern, SE 2005, 'In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor', Clinical Cancer Research, vol. 11, no. 20, pp. 7508-7515. https://doi.org/10.1158/1078-0432.CCR-05-1048
Van Der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ et al. In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor. Clinical Cancer Research. 2005 Oct 15;11(20):7508-7515. https://doi.org/10.1158/1078-0432.CCR-05-1048
Van Der Heijden, Michiel S. ; Brody, Jonathan R. ; Dezentje, David A. ; Gallmeier, Eike ; Cunningham, Steven C. ; Swartz, Michael J. ; Demarzo, Angelo Michael ; Offerhaus, G. Johan A ; Isacoff, William H. ; Hruban, Ralph H ; Kern, Scott E. / In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 20. pp. 7508-7515.
@article{68236a2f41274d7f90a47c0f7295e372,
title = "In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor",
abstract = "Purpose: BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based on the genetic profile of the tumor. Experimental Design: Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway, PL11 (FANCC-mutated) and Hs766T (FANCG-mutated), as Well as several parental pancreatic cancer cell lines with or without mutations in the Fanconi anemia/BRCA2 pathway, were assayed for in vitro and in vivo sensitivities to various chemotherapeutic agents. Results: A distinct dichotomy of drug responses was observed. Fanconi anemia-defective cancer cells were hypersensitive to the cross-linking agents mitomycin C (MMC), cisplatin, chlorambucil, and melphalan but not to 5-fluorouracil, gemcitabine, doxorubicin, etoposide, vinblastine, or paclitaxel. Hypersensitivity to cross-linking agents was confirmed in vivo; FANCC-deficient xenografts of PL11 and BRCA2-deficient xenografts of CAPAN1 regressed on treatment with two different regimens of MMC whereas Fanconi anemia-proficient xenografts did not. The MMC response comprised cell cycle arrest/apoptosis, and necrosis. Xenografts of PL11 also regressed after a single dose of cyclophosphamide whereas xenografts of genetically complemented PL11FANCC did not. Conclusios: MMC or other cross-linking agents as a clinical therapy for pancreatic cancer patients with tumors harboring defects in the Fanconi anemia/BRCA2, pathway should be specifically investigated.",
author = "{Van Der Heijden}, {Michiel S.} and Brody, {Jonathan R.} and Dezentje, {David A.} and Eike Gallmeier and Cunningham, {Steven C.} and Swartz, {Michael J.} and Demarzo, {Angelo Michael} and Offerhaus, {G. Johan A} and Isacoff, {William H.} and Hruban, {Ralph H} and Kern, {Scott E}",
year = "2005",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1048",
language = "English (US)",
volume = "11",
pages = "7508--7515",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor

AU - Van Der Heijden, Michiel S.

AU - Brody, Jonathan R.

AU - Dezentje, David A.

AU - Gallmeier, Eike

AU - Cunningham, Steven C.

AU - Swartz, Michael J.

AU - Demarzo, Angelo Michael

AU - Offerhaus, G. Johan A

AU - Isacoff, William H.

AU - Hruban, Ralph H

AU - Kern, Scott E

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Purpose: BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based on the genetic profile of the tumor. Experimental Design: Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway, PL11 (FANCC-mutated) and Hs766T (FANCG-mutated), as Well as several parental pancreatic cancer cell lines with or without mutations in the Fanconi anemia/BRCA2 pathway, were assayed for in vitro and in vivo sensitivities to various chemotherapeutic agents. Results: A distinct dichotomy of drug responses was observed. Fanconi anemia-defective cancer cells were hypersensitive to the cross-linking agents mitomycin C (MMC), cisplatin, chlorambucil, and melphalan but not to 5-fluorouracil, gemcitabine, doxorubicin, etoposide, vinblastine, or paclitaxel. Hypersensitivity to cross-linking agents was confirmed in vivo; FANCC-deficient xenografts of PL11 and BRCA2-deficient xenografts of CAPAN1 regressed on treatment with two different regimens of MMC whereas Fanconi anemia-proficient xenografts did not. The MMC response comprised cell cycle arrest/apoptosis, and necrosis. Xenografts of PL11 also regressed after a single dose of cyclophosphamide whereas xenografts of genetically complemented PL11FANCC did not. Conclusios: MMC or other cross-linking agents as a clinical therapy for pancreatic cancer patients with tumors harboring defects in the Fanconi anemia/BRCA2, pathway should be specifically investigated.

AB - Purpose: BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based on the genetic profile of the tumor. Experimental Design: Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway, PL11 (FANCC-mutated) and Hs766T (FANCG-mutated), as Well as several parental pancreatic cancer cell lines with or without mutations in the Fanconi anemia/BRCA2 pathway, were assayed for in vitro and in vivo sensitivities to various chemotherapeutic agents. Results: A distinct dichotomy of drug responses was observed. Fanconi anemia-defective cancer cells were hypersensitive to the cross-linking agents mitomycin C (MMC), cisplatin, chlorambucil, and melphalan but not to 5-fluorouracil, gemcitabine, doxorubicin, etoposide, vinblastine, or paclitaxel. Hypersensitivity to cross-linking agents was confirmed in vivo; FANCC-deficient xenografts of PL11 and BRCA2-deficient xenografts of CAPAN1 regressed on treatment with two different regimens of MMC whereas Fanconi anemia-proficient xenografts did not. The MMC response comprised cell cycle arrest/apoptosis, and necrosis. Xenografts of PL11 also regressed after a single dose of cyclophosphamide whereas xenografts of genetically complemented PL11FANCC did not. Conclusios: MMC or other cross-linking agents as a clinical therapy for pancreatic cancer patients with tumors harboring defects in the Fanconi anemia/BRCA2, pathway should be specifically investigated.

UR - http://www.scopus.com/inward/record.url?scp=27144532118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144532118&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1048

DO - 10.1158/1078-0432.CCR-05-1048

M3 - Article

C2 - 16243825

AN - SCOPUS:27144532118

VL - 11

SP - 7508

EP - 7515

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -